{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:05:09Z","timestamp":1786118709549,"version":"build-2736575974"},"reference-count":39,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2007,3]]},"DOI":"10.1097\/01.pap.0000249920.70815.2d","type":"journal-article","created":{"date-parts":[[2007,3,19]],"date-time":"2007-03-19T03:49:54Z","timestamp":1174276194000},"page":"213-220","source":"Crossref","is-referenced-by-count":3,"title":["Ciprofibrate Treatment Decreases Non-high Density Lipoprotein Cholesterol and Triglycerides and Increases High Density Lipoprotein Cholesterol in Patients With Frederickson Type IV Dyslipidemia Phenotype"],"prefix":"10.1097","volume":"14","author":[{"given":"Valmore","family":"Berm\u00fadez-Pirela","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aida","family":"Souki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cl\u00edmaco","family":"Cano-Ponce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Berm\u00fadez-Arias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edgardo","family":"Mengual-Moreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elliuz","family":"Leal-Gonzalez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Lemus-Antepaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayela Cabrera","family":"de Bravo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anilsa Amell","family":"de D\u00edaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nilka Leal","family":"de Pirela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel","family":"Cano-Pe\u00f1aloza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo","family":"Puche-Medina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Navlet","family":"Arraiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Reyna-Villazmil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Freddy","family":"Contreras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zafar H","family":"Israili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Valasco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-16-20210202","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1067\/mhj.2003.45","article-title":"High triglycerides\/low high density lipoprotein cholesterol, ischemic electrocardiogram changes, and risk of ischemic heart disease.","volume":"145","author":"Jeppesen","year":"2003","journal-title":"Am Heart J"},{"key":"R2-16-20210202","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1161\/01.HYP.36.2.226","article-title":"High triglycerides and low HDL cholesterol and blood pressure and risk of ischemic heart disease.","volume":"36","author":"Jeppesen","year":"2000","journal-title":"Hypertension"},{"key":"R3-16-20210202","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1046\/j.1365-2796.2001.00864.x","article-title":"The dysmetabolic syndrome Review.","volume":"250","author":"Groop","year":"2001","journal-title":"J Intern Med"},{"key":"R4-16-20210202","first-page":"237","article-title":"New and classical risk factors: the Munster heart study (PROCAM).","volume":"2","author":"Assmann","year":"1997","journal-title":"Eur J Med Res"},{"key":"R6-16-20210202","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1016\/S0022-2275(20)31581-9","article-title":"High prevalence of low HDL cholesterol concentrations and mixed hyperlipidemia in a Mexican nation wide survey.","volume":"42","author":"Aguilar-Salinas","year":"2001","journal-title":"J Lipid Res"},{"key":"R7-16-20210202","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1001\/jama.285.19.2486","article-title":"Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP).","volume":"285","year":"2001","journal-title":"JAMA"},{"issue":"Suppl A","key":"R8-16-20210202","doi-asserted-by":"crossref","first-page":"A43","DOI":"10.1016\/j.ehjsup.2004.01.010","article-title":"Non-high-density lipoprotein cholesterol as a risk factor: addressing risk associated with apolipoprotein B-containing lipoproteins.","volume":"6","author":"Chapman","year":"2004","journal-title":"Eur Heart J"},{"key":"R9-16-20210202","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1185\/030079905X74952","article-title":"LDL-C\/HDL-C ratio in subjects with cardiovascular disease and a low LDL-C: results of the RADAR (Rosuvastatin and Atorvastatin in different Dosages And Reverse cholesterol transport) study.","volume":"21","author":"Jukema","year":"2005","journal-title":"Curr Med Res Opin"},{"key":"R10-16-20210202","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.atherosclerosis.2005.04.002","article-title":"Fibrates and coronary risk reduction Review.","volume":"182","author":"Steiner","year":"2005","journal-title":"Atherosclerosis"},{"key":"R11-16-20210202","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.2165\/00003495-200464190-00003","article-title":"Role of fibric acid derivatives in the management of risk factors for coronary heart disease Review.","volume":"64","author":"Despres","year":"2004","journal-title":"Drugs"},{"issue":"Suppl 1","key":"R12-16-20210202","first-page":"S34","article-title":"Mechanism of action of fibrates Review.","volume":"69","author":"Shepherd","year":"1993","journal-title":"Postgrad Med J"},{"key":"R13-16-20210202","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/1043-6618(92)90232-Z","article-title":"Mode of action of fibrates Review.","volume":"26","author":"Catapano","year":"1992","journal-title":"Pharmacol Res"},{"key":"R14-16-20210202","doi-asserted-by":"crossref","first-page":"5336","DOI":"10.1002\/j.1460-2075.1996.tb00918.x","article-title":"PPAR and PPAR activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene.","volume":"15","author":"Schoonjans","year":"1996","journal-title":"EMBO J"},{"key":"R15-16-20210202","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1172\/JCI117717","article-title":"Fibrates downregulate apolipoprotein C-III expression independent of induction of peroxisomal acyl coenzyme A oxidase. A potential mechanism for the hypolipidemic action of fibrates.","volume":"95","author":"Staels","year":"1995","journal-title":"J Clin Invest"},{"key":"R16-16-20210202","doi-asserted-by":"crossref","first-page":"13470","DOI":"10.1074\/jbc.270.22.13470","article-title":"Mode of action of peroxisome proliferators as hypolipidemic drugs. Suppression of apolipoprotein C-III.","volume":"270","author":"Hertz","year":"1995","journal-title":"J Biol Chem"},{"key":"R17-16-20210202","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/j.1432-1033.1995.tb20797.x","article-title":"Regulation of rat liver apolipoprotein A-I, apolipoprotein A-II, and acyl-coenzyme A oxidase gene expression by fibrates and dietary fatty acids.","volume":"232","author":"Berthou","year":"1995","journal-title":"Eur J Biochem"},{"issue":"Suppl","key":"R18-16-20210202","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1016\/S0021-9150(97)00313-4","article-title":"Regulation of apo A-I gene expression by fibrates Review.","volume":"137","author":"Staels","year":"1998","journal-title":"Atherosclerosis"},{"key":"R19-16-20210202","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1097\/00041433-199102000-00009","article-title":"Fibric acid derivatives.","volume":"2","author":"Gaw","year":"1991","journal-title":"Curr Opin Lipidol"},{"key":"R20-16-20210202","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1097\/00041433-199302000-00007","article-title":"Triglyceride-lowering agents: fibrates and nicotinic acid.","volume":"4","author":"Larsen","year":"1993","journal-title":"Curr Opin Lipidol"},{"key":"R21-16-20210202","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1161\/01.CIR.98.19.2088","article-title":"Mechanism of action of fibrates on lipid and lipoprotein metabolism Review.","volume":"98","author":"Staels","year":"1998","journal-title":"Circulation"},{"key":"R22-16-20210202","doi-asserted-by":"crossref","first-page":"4312","DOI":"10.1073\/pnas.94.9.4312","article-title":"Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors and.","volume":"94","author":"Forman","year":"1997","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R23-16-20210202","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/S0022-2275(20)42003-6","article-title":"Role of the peroxisome proliferator-activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expressio. Review.","volume":"37","author":"Schoonjans","year":"1996","journal-title":"J Lipid Res"},{"key":"R24-16-20210202","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1093\/clinchem\/18.6.499","article-title":"Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.","volume":"18","author":"Friedewald","year":"1972","journal-title":"Clin Chem"},{"key":"R25-16-20210202","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1111\/j.1749-6632.2000.tb06318.x","article-title":"Endothelial dysfunction, hemodynamic forces, and atherogenesis.","volume":"902","author":"Gimbrone","year":"2000","journal-title":"Ann N Y Acad Sci"},{"key":"R26-16-20210202","first-page":"34","article-title":"Noninvasive assessment of cardiovascular risk: from Framingham to the future Review.","volume":"1","author":"Vogel","year":"2000","journal-title":"Rev Cardiovasc Med"},{"key":"R27-16-20210202","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1001\/jama.1987.03390160062027","article-title":"Cholesterol and mortality: 30 years of follow-up from the Framingham Study.","volume":"257","author":"Anderson","year":"1987","journal-title":"JAMA"},{"key":"R28-16-20210202","first-page":"284","article-title":"HMG-CoA reductase inhibition in the treatment of atherosclerosis: effects beyond lipid lowering.","volume":"9","author":"Marz","year":"2002","journal-title":"J Kardiol"},{"key":"R29-16-20210202","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.2337\/diacare.27.6.1496","article-title":"Lipids and lipoproteins in patients with type 2 diabetes.","volume":"27","author":"Krauss","year":"2004","journal-title":"Diabetes Care"},{"key":"R30-16-20210202","doi-asserted-by":"crossref","first-page":"3738","DOI":"10.1210\/jc.2003-030191","article-title":"Action of ciprofibrate in type IIB hyperlipoproteinemia: modulation of the atherogenic lipoprotein phenotype and stimulation of high-density lipoprotein-mediated cellular cholesterol efflux.","volume":"88","author":"Guerin","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"R31-16-20210202","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/0021-9150(94)90108-2","article-title":"Effects of ciprofibrate on LDL metabolism in man.","volume":"108","author":"Gaw","year":"1994","journal-title":"Atherosclerosis"},{"key":"R32-16-20210202","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.2337\/diacare.26.5.1513","article-title":"On behalf of the VA-HIT Study Group. Insulin resistance and cardiovascular events with low HDL cholesterol: the Veterans Affairs HDL Intervention Trial (VA-HIT).","volume":"26","author":"Robins","year":"2003","journal-title":"Diabetes Care"},{"key":"R33-16-20210202","doi-asserted-by":"crossref","first-page":"3486","DOI":"10.2337\/diabetes.51.12.3486","article-title":"Mechanisms of the triglyceride- and cholesterol-lowering effect of fenofibrate in hyperlipidemic type 2 diabetic patients.","volume":"51","author":"Forcheron","year":"2002","journal-title":"Diabetes"},{"key":"R34-16-20210202","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1161\/01.CIR.101.20.2411","article-title":"CLA-1\/SR-BI is expressed in atherosclerotic lesion macrophages and regulated by activators of peroxisome proliferator-activated receptors.","volume":"101","author":"Chinetti","year":"2000","journal-title":"Circulation"},{"key":"R35-16-20210202","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1001\/archinte.161.11.1413","article-title":"Non-high-density lipoprotein cholesterol level as a predictor of cardiovascular disease mortality.","volume":"161","author":"Cui","year":"2001","journal-title":"Arch Intern Med"},{"key":"R36-16-20210202","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1053\/euhj.2000.2402","article-title":"Cardiovascular risk factors and 10-year all-cause mortality in elderly European male populations; the FINE study. Finland, Italy, Netherlands, Elderly.","volume":"22","author":"Menotti","year":"2001","journal-title":"Eur Heart J"},{"key":"R37-16-20210202","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1007\/s00125-003-1141-5","article-title":"A combination of high concentrations of serum triglyceride and non-high-density-lipoprotein-cholesterol is a risk factor for cardiovascular disease in subjects with abnormal glucose metabolism: the Hoorn Study.","volume":"46","author":"Bos","year":"2003","journal-title":"Diabetologia"},{"key":"R38-16-20210202","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/S0022-2275(20)39173-2","article-title":"Effects of age, gender, and menopausal status on plasma low density lipoprotein cholesterol and apolipoprotein B levels in the Framingham Offspring Study.","volume":"35","author":"Schaefer","year":"1994","journal-title":"J Lipid Res"},{"issue":"Suppl 3","key":"R39-16-20210202","doi-asserted-by":"crossref","first-page":"32","DOI":"10.2165\/00003495-198800363-00009","article-title":"Helsinki Heart Study. New perspectives in the prevention of coronary heart disease.","volume":"36","author":"Huttunen","year":"1988","journal-title":"Drugs"},{"key":"R40-16-20210202","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1475-2840-3-8","article-title":"Ciprofibrate therapy in patients with hypertriglyceridemia and low high density lipoprotein (HDL)-cholesterol: greater reduction of non-HDL cholesterol in subjects with excess body weight (the CIPROAMLAT study).","volume":"3","author":"Aguilar-Salinas","year":"2004","journal-title":"Cardiovasc Diabetol"}],"container-title":["American Journal of Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/01.pap.0000249920.70815.2d","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T16:35:31Z","timestamp":1786034131000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00045391-200703000-00016"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,3]]},"references-count":39,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2007]]}},"URL":"https:\/\/doi.org\/10.1097\/01.pap.0000249920.70815.2d","relation":{},"ISSN":["1075-2765"],"issn-type":[{"value":"1075-2765","type":"print"}],"subject":[],"published":{"date-parts":[[2007,3]]}}}